COPYRIGHT© 2018 吉林紫鑫药业股份有限公司
Jilin Zixin Pharmaceutical Co., Ltd.'s pre-approval opinion of independent directors submitted to the board of directors for rel
Jilin Zixin Pharmaceutical Co., Ltd.
Pre-approval opinions of independent directors submitted to the board of directors for related party transactions
According to the "Guiding Opinions on Establishing Independent Director System in Listed Companies", "Articles of Association", "Rules of Company Board of Directors" and other relevant rules and regulations, as Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as "the company") The independent directors carefully reviewed the relevant information submitted by the company to us regarding the sale of wild ginseng, and based on the relevant information to other directors and related personnel of the company, based on the objective and independent judgment of the individual, the company will be the company. The related transaction of the sale of wild ginseng in the book inventory to the first major shareholder Dunhua Kangping Investment Co., Ltd. was based on the premise that the major shareholder solved the actual difficulties of the company, which enabled the company to realize the sales of wild ginseng in a short period of time. To achieve capital recovery, avoid market risks, solve the problem of not finding a convincing market trading quotation system, and completely eliminate the company's non-standard unreserved audit report; the company uses wild ginseng purchase cost plus period holding cost to do For pricing basis, there is no damage to the company and the company's small and medium-sized shares We believe that the related transaction proposal was proposed by the company based on the principle of prudence and complies with relevant laws and regulations and the Articles of Association. We agree to submit the related party transaction proposal to the eleventh meeting of the fifth board of directors for deliberation.
Signature of Independent Director: Fu Wei Li Fei Wang Xu